Firalis

Executive Summary

Firalis is a French biotechnology company established in 2005, headquartered in the BioValley region of Huningue. The company operates as a contract research organization (CRO) specializing in biomarker discovery, development, and regulatory qualification for pharmaceutical and biotech partners. Additionally, Firalis is advancing its own pipeline of in-vitro diagnostic (IVD) kits targeting inflammatory, cardiovascular, neurodegenerative, and drug-induced organ injury biomarkers. By leveraging its expertise in translational biomarker solutions, Firalis aims to address unmet needs in precision medicine and patient stratification, positioning itself as both a service provider and a future commercial diagnostics player. Despite limited public information on funding or revenue, the company's long-standing presence in the diagnostics space suggests a stable, albeit niche, market position. Private ownership and a focus on regulatory-grade biomarker validation provide a foundation for potential growth.

Upcoming Catalysts (preview)

• Q4 2026CE marking or FDA clearance of first in-house IVD kit (e.g., inflammation biomarker)60% success
• Q3 2026Major pharma partnership for biomarker services in neurodegenerative or cardiovascular area70% success
• Q2 2027Completion of clinical validation study for drug-induced organ injury biomarker panel65% success